Patents by Inventor Longqing TANG
Longqing TANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220235324Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.Type: ApplicationFiled: February 10, 2022Publication date: July 28, 2022Inventors: Xiangjun ZHOU, Yifan MA, Yanyan HAN, Jin LI, Longqing TANG, Junyun LIU, Dongyun WU
-
Publication number: 20220211829Abstract: The present invention provides a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual are provided. Methods of preparing the activated T cells, methods of monitoring the treatment, and methods of cloning tumor-specific T cell receptors are further disclosed. An isolated population of cells comprising the activated T cells, as well as compositions and kits useful for cancer immunotherapy are also provided.Type: ApplicationFiled: January 13, 2022Publication date: July 7, 2022Inventors: Xiangjun ZHOU, Jin LI, Yanyan HAN, Dongyun WU, Junyun LIU, Longqing TANG, Ran TAO
-
Patent number: 11248208Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.Type: GrantFiled: March 29, 2019Date of Patent: February 15, 2022Assignees: SYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.Inventors: Xiangjun Zhou, Yifan Ma, Yanyan Han, Jin Li, Longqing Tang, Junyun Liu, Dongyun Wu
-
Patent number: 11229689Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: GrantFiled: March 17, 2021Date of Patent: January 25, 2022Assignee: SYZ Cell Therapy Co.Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Longqing Tang, Ran Tao
-
Patent number: 11219675Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: GrantFiled: December 8, 2020Date of Patent: January 11, 2022Assignee: SYZ Cell Therapy Co.Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Ran Tao, Longqing Tang
-
Publication number: 20210268083Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: ApplicationFiled: March 17, 2021Publication date: September 2, 2021Inventors: Xiangjun ZHOU, Jin LI, Yanyan HAN, Dongyun WU, Junyun LIU, Longqing TANG, Ran TAO
-
Publication number: 20210113676Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: ApplicationFiled: December 8, 2020Publication date: April 22, 2021Inventors: Xiangjun ZHOU, Jin LI, Yanyan HAN, Dongyun WU, Junyun LIU, Ran TAO, Longqing TANG
-
Patent number: 10967054Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: GrantFiled: March 11, 2016Date of Patent: April 6, 2021Assignee: SYZ CELL THERAPY CO.Inventors: Xiangjun Zhou, Jin Li, Yanyan Han, Dongyun Wu, Junyun Liu, Longqing Tang
-
Publication number: 20210017495Abstract: The present invention provides methods of preparing a population of activated T cells by co-culturing T cells with dendritic cells loaded with a plurality of tumor antigen peptides. Also provided are methods of treating cancer in an individual using the activated T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.Type: ApplicationFiled: March 29, 2019Publication date: January 21, 2021Inventors: Xiangjun ZHOU, Yifan MA, Yanyan HAN, Jin LI, Longqing TANG, Junyun LIU, Dongyun WU
-
Patent number: 10526659Abstract: Biomarkers and methods related to microbiota for predicting the risk of a disease, particularly colorectal cancer (CRC), are described.Type: GrantFiled: February 5, 2016Date of Patent: January 7, 2020Assignees: BGI Shenzhen Co., Limited, BGI ShenzhenInventors: Qiang Feng, Dongya Zhang, Longqing Tang, Jun Wang
-
Publication number: 20180078624Abstract: Provided is a method of treating a cancer in an individual using activated T cells or PBMCs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be used singly or in combination with an immune checkpoint inhibitor. Also provided are precision therapy methods customized for the individual using neoantigen peptides or based on the mutation load in the tumor of the individual, methods of preparing the activated T cells, methods of monitoring the treatment, methods of cloning tumor-specific T cell receptors, an isolated population of cells comprising the activated T cells, and compositions and kits useful for cancer immunotherapy.Type: ApplicationFiled: March 11, 2016Publication date: March 22, 2018Applicant: SYZ CELL THERAPY CO.Inventors: Xiangjun ZHOU, Jin LI, Yanyan HAN, Dongyun WU, Junyun LIU, Ran TAO, Longqing TANG
-
Publication number: 20160160296Abstract: Biomarkers and methods related to microbiota for predicting the risk of a disease, particularly colorectal cancer (CRC), are described.Type: ApplicationFiled: February 5, 2016Publication date: June 9, 2016Inventors: Qiang FENG, Dongya ZHANG, Longqing TANG, Jun WANG